 "Alembic Pharmaceuticals plans to raise up to Rs 5 bn through issue of NCDs")
Drug firm Alembic Pharmaceuticals Thursday said it plans to raise up to Rs 5 billion through the issue of non-convertible debentures (NCDs) on private placement basis.
The company's board of directors Thursday approved the issue of unsecured listed redeemable NCDs of up to Rs 5 billion on private placement basis under a shelf disclosure document in multiple tranches, Alembic Pharmaceuticals said in a filing to the BSE.
The board also constituted NCD Committee for issue and allotment of NCDs, it added.
The company, however, did not disclose what it intends to do with the raised money.
Shares of Alembic Pharmaceuticals were Thursday trading at Rs 615.90 per scrip on the BSE, down 2.05 per cent from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app